ClinicalTrials.gg
CompletedNCT03903822Updated Mar 29, 2021Results posted

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

A Phase 2 interventional study of PF-06700841 and Vehicle (Placebo) in Atopic Dermatitis, sponsored by Pfizer. Completed at 76 sites in 10 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-29.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.

Enrollment
15th of 47
292 · median 121
Started
2019
with 7 others
Phase 2
13 of 58
1 open now
Registered
22nd of 58
by date

Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 15th largest by enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2019, is one of 13 in phase 2, and was the 22nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dermatitis, Atopic by Pfizer, or all of them as a file.
02

Study summary

This study is being conducted to provide data on efficacy, safety, tolerability and PK of multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of mild to moderate atopic dermatitis (AD). The study is intended to enable selection of the dose and dosing regimen (once daily [QD] vs twice daily [BID] application) for the future clinical development of topical PF-06700841.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Mild-to-Moderate Atopic Dermatitis
  • topical
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Atopic Dermatitis for at least 3 months
  • Investigator's Global Assessment (IGA) Score of 2 or 3
  • Eczema Area Severity Index (EASI) score of 3-21
  • Body Surface Area (BSA) of 2-20%
  • Peak pruritus-Numerical Rating Scale (PPNRS) of Grade 2 or more

Exclusion criteria

Exclusion Criteria:

  • Other forms of dermatological diseases (other than atopic dermatitis)
  • Fitzpatrick skin type score greater than 5
  • abnormal , vital signs, and laboratory values
  • Infection with , , herpes zoster or tuberculosis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
292 participants (actual)

Study arms

  • Experimental
    PF-06700841 0.1% cream QD

    PF-06700841 0.1% cream applied once daily (QD)

    Drug: PF-06700841

  • Experimental
    PF-06700841 0.3% cream QD

    PF-06700841 0.3% cream applied once daily (QD)

    Drug: PF-06700841

  • Experimental
    PF-06700841 1% cream QD

    PF-06700841 1% cream applied once daily (QD)

    Drug: PF-06700841

  • Experimental
    PF-06700841 3% cream QD

    PF-06700841 3% cream applied once daily (QD)

    Drug: PF-06700841

  • Experimental
    PF-06700841 0.3% cream BID

    PF-06700841 0.3% cream applied twice daily (BID)

    Drug: PF-06700841

  • Experimental
    PF-06700841 1% cream BID

    PF-06700841 1% cream applied twice daily (BID)

    Drug: PF-06700841

  • Placebo comparator
    Vehicle cream QD

    Vehicle cream applied once daily (QD)

    Drug: Vehicle (Placebo)

  • Placebo comparator
    Vehicle cream BID

    Vehicle cream applied twice daily (BID)

    Drug: Vehicle (Placebo)

Interventions

  • PF-06700841 topical cream

  • DrugVehicle (Placebo)

    Vehicle topical cream

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation

    EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( >=2) Points at Week 6: Non-responder Imputation

    IGA assesses severity of participant's AD on a 5 point scale. 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Higher scores indicating more severity of AD. Assessment excluded soles, palms and scalp.

    Time frame: Baseline, Week 6

  2. Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation

    EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

    Time frame: Baseline, Week 6

  3. Percentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation

    The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

    Time frame: Baseline, Weeks 1, 2, 3, 4 and 6

  4. Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation

    The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

  5. Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit

    4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

  6. Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation

    EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

    Time frame: Baseline, Weeks 1, 2, 3, 4 and 6

  7. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and all non-SAEs.

    Time frame: Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)

  8. Number of Participants With Pre-defined Criteria For Vital Signs

    Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) sitting DBP: change of \>= 20 millimeter of mercury (mmHg) increase, b) sitting DBP: change of \>=20mmHg decrease, c) supine DBP: less than (\<) 50 mmHg, d) supine DBP: change of \>= 20mmHg increase, e) supine DBP: change of \>= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) sitting SBP: \<90 mmHg, b) sitting SBP: change of \>=30mmHg increase, c) sitting SBP: change of \>=30mmHg decrease, d) supine SBP: change of \>=30mmHg increase, e) supine SBP: change of \>=30mmHg decrease and f) Supine SBP: value \<90mmHg.

    Time frame: Baseline up to Week 6

  9. Number of Participants With Laboratory Abnormalities

    Hemoglobin (HGB),hematocrit,erythrocytes (ery.),HDL cholesterol (chl.)\<0.8\*lower limit of normal(LLN);reticulocytes (ret.), ret./ery. (%)\<0.5\*LLN,\>1.5\*upper limit of normal (ULN);ery. mean corpuscular (EMC) volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leukocytes (leu.),glucose\<0.6\*LLN,\>1.5\*ULN;lymphocytes (lym.), lym./leu.(%), neutrophils (neu.), neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;basophils (bas.), bas./leu.(%), eosinophils (eos.), eos./leu., monocytes (mon.), mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20.

    Time frame: Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)

  10. Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings

    Clinically significant ECG criteria included PR interval: value greater than (\>) 280 millisecond (msec), percentage change greater than equal to (\>=) 25/50 percentage, QRS interval: value \>120 msec, percentage change \>= 50% and QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30\<=change\<60.

    Time frame: Baseline up to Week 6

  11. Change From Baseline in Clinical Chemistry-Lactate Dehydrogenase Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

    Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

  12. Change From Baseline in Clinical Chemistry- Protein and Albumin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

    Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

  13. Change From Baseline in Clinical Chemistry- Urea Nitrogen, Urate, Calcium and Glucose Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

    Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

  14. Change From Baseline in Clinical Chemistry- Sodium, Potassium, Chloride and Bicarbonate Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

    Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

  15. Change From Baseline in Hematology- Hemoglobin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

    Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

  16. Change From Baseline in Hematology - Hematocrit, Reticulocytes/Erythrocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes, Basophils/Leukocytes, Eosinophils/Leukocytes and Monocytes/Leukocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

    Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

  17. Change From Baseline in Hematology- Erythrocytes and Reticulocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

    Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

  18. Change From Baseline in Hematology- Platelets, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils and Monocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

    Time frame: Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

  19. Change From Baseline in Lipids Profile Values at Week 6

    Lipid parameters that were assessed: high density lipoprotein (HDL) cholesterol, triglycerides, cholesterol, low density lipoprotein (LDL) cholesterol.

    Time frame: Baseline, Week 6

  20. Change From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 6

    Mean change in total cholesterol/HDL cholesterol ratio was assessed and reported.

    Time frame: Baseline, Week 6

  21. Change From Baseline in Electrocardiogram (ECG) Parameter- Heart Rate at Weeks 2 and 6

    Time frame: Baseline, Weeks 2 and 6

  22. Change From Baseline in PR, QRS, QTCF and QT Interval at Weeks 2 and 6

    Time frame: Baseline, Weeks 2 and 6

  23. Change From Baseline in Vital Signs- Blood Pressure (BP) at Weeks 2 and 6

    Blood pressure included supine and sitting systolic and diastolic BP.

    Time frame: Baseline, Weeks 2 and 6

  24. Change From Baseline in Vital Signs- Pulse Rate at Weeks 2 and 6

    Time frame: Baseline, Weeks 2 and 6

  25. Change From Baseline in Vital Signs- Temperature at Weeks 2 and 6

    Time frame: Baseline, Weeks 2 and 6

  26. Number of Participants With Each Severity Grade in Local Tolerability Assessments

    Local tolerability skin assessments were performed by the investigator and graded based on severity from grade 0 to 4 as: grade 0=none (no evidence of local intolerance); grade 1=mild (minimal erythema and/or oedema, slight glazed appearance); grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology) grade 3=severe (erythema, oedema glazing with fissures, few vesicles or papules consider removing topical agent \[if still in place\]) and grade 4= very severe (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\]). Higher grades indicated worsening of condition. Only those categories in which at least 1 participant had data were reported.

    Time frame: Day 1 and any day on of Week 1, 2, 4, 6: pre dose (before application of IP) and post dose (after application of IP); Follow up visit (28 days after last dose of study drug = maximum up to Day 71) and Early termination (anytime within week 11)

07

Results

Posted Mar 29, 2021

Participant flow

Treatment Phase (6 Weeks)
Participant flow — Treatment Phase (6 Weeks)
MilestoneVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Started3737363736363637
Completed2827333231253133
Not completed9103551154
Withdrew: Adverse event33111610
Withdrew: Lack of efficacy00001100
Withdrew: Lost to follow-up00000011
Withdrew: Physician decision02000000
Withdrew: Pregnancy00011000
Withdrew: Protocol violation00010000
Withdrew: Withdrawal by subject24221233
Withdrew: Refused further treatment20000100
Withdrew: Other21001100
Follow up Phase (4 Weeks)
Participant flow — Follow up Phase (4 Weeks)
MilestoneVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Started3737363736363637
Completed2929323332283131
Not completed88444856
Withdrew: Adverse event32110510
Withdrew: Lack of efficacy00001000
Withdrew: Lost to follow-up20000013
Withdrew: Pregnancy00011000
Withdrew: Withdrawal by subject25322233
Withdrew: Refused further study procedures00000100
Withdrew: Other11000000

Outcome measures

PrimaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation

EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation
Percent changeVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation-44.4 (-57.3 to -31.6)-58.3 (-71.2 to -45.5)-64.6 (-77.1 to -52.1)-70.1 (-82.1 to -58.0)-67.9 (-80.6 to -55.3)-47.6 (-57.5 to -37.7)-58.6 (-67.5 to -49.7)-75.0 (-83.8 to -66.2)
Statistical analysis
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · ANCOVA · p = 0.1040 · Least square (ls) mean difference: -13.9 · 90% CI -32.1 to 4.3
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · ANCOVA · p = 0.0334 · Ls mean difference: -20.2 · 90% CI -38.3 to -2.1
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · ANCOVA · p = 0.0086 · Ls mean difference: -25.6 · 90% CI -43.3 to -8.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · ANCOVA · p = 0.0158 · Ls mean difference: -23.5 · 90% CI -41.5 to -5.5
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · ANCOVA · p = 0.0879 · Ls mean difference: -11.0 · 90% CI -24.3 to 2.4
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · ANCOVA · p = 0.0004 · Ls mean difference: -27.4 · 90% CI -40.7 to -14.1
SecondaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( >=2) Points at Week 6: Non-responder Imputation

IGA assesses severity of participant's AD on a 5 point scale. 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Higher scores indicating more severity of AD. Assessment excluded soles, palms and scalp.

Time frame:
Baseline, Week 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( >=2) Points at Week 6: Non-responder Imputation
Percentage of participantsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( >=2) Points at Week 6: Non-responder Imputation10.8 (4.8 to 22.2)29.7 (18.5 to 43.3)33.3 (21.3 to 47.0)40.5 (28.0 to 54.4)44.4 (30.2 to 59.1)13.9 (6.9 to 25.4)33.3 (21.3 to 47.0)27.0 (15.5 to 40.2)
Statistical analysis
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.0244 · Risk difference (rd): 18.9 · 90% CI 2.4 to 34.7
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.0113 · Risk difference (rd): 22.5 · 90% CI 4.8 to 38.6
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0018 · Risk difference (rd): 29.7 · 90% CI 11.0 to 45.7
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0007 · Risk difference (rd): 33.6 · 90% CI 13.7 to 49.9
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.0289 · Risk difference (rd): 19.4 · 90% CI 1.8 to 36.5
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.1145 · Risk difference (rd): 13.1 · 90% CI -2.9 to 29.6
SecondaryChange From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation

EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation
Units on a scaleVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation-3.2 (-4.1 to -2.3)-4.5 (-5.4 to -3.6)-4.6 (-5.5 to -3.7)-4.8 (-5.7 to -3.9)-5.5 (-6.4 to -4.7)-3.6 (-4.3 to -3.0)-4.4 (-5.0 to -3.8)-5.3 (-5.9 to -4.7)
Statistical analysis
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · ANCOVA · p = 0.0488 · Ls mean difference: -1.31 · 90% CI -2.61 to -0.01
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · ANCOVA · p = 0.0413 · Ls mean difference: -1.37 · 90% CI -2.66 to -0.07
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · ANCOVA · p = 0.0200 · Ls mean difference: -1.59 · 90% CI -2.86 to -0.32
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · ANCOVA · p = 0.0011 · Ls mean difference: -2.33 · 90% CI -3.58 to -1.08
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · ANCOVA · p = 0.0727 · Ls mean difference: -0.78 · 90% CI -1.66 to 0.10
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · ANCOVA · p = 0.0010 · Ls mean difference: -1.64 · 90% CI -2.52 to -0.77
SecondaryPercentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

Time frame:
Baseline, Weeks 1, 2, 3, 4 and 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation
Percentage of participantsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
At Week 116.2 (7.3 to 29.3)16.7 (7.5 to 30.2)20.0 (11.0 to 33.8)29.7 (18.5 to 43.3)44.4 (30.2 to 59.1)13.9 (6.9 to 25.4)28.6 (16.4 to 41.9)25.7 (15.4 to 39.2)
At Week 224.3 (14.5 to 37.0)30.6 (18.9 to 44.0)42.9 (30.0 to 58.1)48.6 (34.3 to 63.0)61.1 (47.0 to 74.6)25.0 (14.9 to 38.0)45.7 (31.7 to 60.8)37.1 (23.6 to 52.2)
At Week 321.6 (11.2 to 34.3)38.9 (25.4 to 53.0)48.6 (33.8 to 63.5)59.5 (45.6 to 72.0)58.3 (44.0 to 71.0)33.3 (21.3 to 47.0)51.4 (36.5 to 66.2)57.1 (41.9 to 70.0)
At Week 435.1 (22.2 to 49.3)38.9 (25.4 to 53.0)51.4 (36.5 to 66.2)62.2 (48.0 to 75.2)58.3 (44.0 to 71.0)30.6 (18.9 to 44.0)60.0 (44.8 to 74.0)60.0 (44.8 to 74.0)
At Week 640.5 (28.0 to 54.4)41.7 (29.0 to 56.0)51.4 (36.5 to 66.2)56.8 (43.2 to 70.7)61.1 (47.0 to 74.6)30.6 (18.9 to 44.0)60.0 (44.8 to 74.0)60.0 (44.8 to 74.0)
Statistical analysis
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.5246 · Risk difference (rd): 0.5 · 90% CI -14.7 to 16.4
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.3906 · Risk difference (rd): 3.8 · 90% CI -12.5 to 19.9
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.1193 · Risk difference (rd): 13.5 · 90% CI -3.2 to 30.6
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0048 · Risk difference (rd): 28.2 · 90% CI 8.8 to 45.5
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.0777 · Risk difference (rd): 14.7 · 90% CI -2.0 to 31.1
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.1245 · Risk difference (rd): 11.8 · 90% CI -4.3 to 28.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.3322 · Risk difference (rd): 6.2 · 90% CI -12.2 to 24.4
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.0535 · Risk difference (rd): 18.5 · 90% CI -0.3 to 36.5
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0159 · Risk difference (rd): 24.3 · 90% CI 4.5 to 41.9
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0008 · Risk difference (rd): 36.8 · 90% CI 15.4 to 54.0
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.0386 · Risk difference (rd): 20.7 · 90% CI 1.5 to 38.8
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.1485 · Risk difference (rd): 12.1 · 90% CI -6.4 to 30.3
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.0620 · Risk difference (rd): 17.3 · 90% CI -0.8 to 34.8
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.0089 · Risk difference (rd): 26.9 · 90% CI 6.5 to 44.4
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0005 · Risk difference (rd): 37.8 · 90% CI 17.5 to 54.7
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0007 · Risk difference (rd): 36.7 · 90% CI 15.4 to 54.0
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.0711 · Risk difference (rd): 18.1 · 90% CI -2.0 to 37.5
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0266 · Risk difference (rd): 23.8 · 90% CI 2.7 to 42.5
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.4173 · Risk difference (rd): 3.8 · 90% CI -15.3 to 23.1
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.1096 · Risk difference (rd): 16.3 · 90% CI -4.3 to 35.6
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0133 · Risk difference (rd): 27.0 · 90% CI 6.1 to 45.7
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0304 · Risk difference (rd): 23.2 · 90% CI 2.6 to 41.7
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.0078 · Risk difference (rd): 29.4 · 90% CI 7.2 to 47.6
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0078 · Risk difference (rd): 29.4 · 90% CI 7.2 to 47.6
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.4966 · Risk difference (rd): 1.1 · 90% CI -18.4 to 20.4
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.2753 · Risk difference (rd): 10.9 · 90% CI -9.3 to 30.1
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.1036 · Risk difference (rd): 16.2 · 90% CI -4.2 to 35.7
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0457 · Risk difference (rd): 20.6 · 90% CI 0.4 to 39.6
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.0078 · Risk difference (rd): 29.4 · 90% CI 7.2 to 47.6
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0078 · Risk difference (rd): 29.4 · 90% CI 7.2 to 47.6
SecondaryPercentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation
Percentage of participantsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
At Week 10.0 (0.0 to 8.2)3.3 (0.4 to 14.0)3.1 (0.3 to 13.1)16.1 (8.1 to 29.7)10.7 (4.0 to 23.8)3.3 (0.4 to 14.0)3.3 (0.4 to 14.0)11.1 (4.2 to 24.8)
At Week 29.1 (3.4 to 20.2)10.0 (3.7 to 22.1)9.4 (3.5 to 20.7)19.4 (8.8 to 32.7)25.0 (13.9 to 40.0)10.0 (3.7 to 22.1)13.3 (5.9 to 27.9)33.3 (20.4 to 50.0)
At Week 312.1 (5.4 to 25.1)23.3 (12.9 to 37.6)15.6 (7.8 to 28.7)32.3 (18.7 to 48.2)32.1 (19.7 to 47.3)10.0 (3.7 to 22.1)20.0 (9.1 to 33.9)37.0 (22.1 to 54.7)
At Week 418.2 (8.2 to 31.3)26.7 (14.0 to 41.6)28.1 (17.0 to 43.3)35.5 (21.3 to 51.8)50.0 (33.3 to 66.7)10.0 (3.7 to 22.1)30.0 (18.2 to 45.5)37.0 (22.1 to 54.7)
At Week 618.2 (8.2 to 31.3)30.0 (18.2 to 45.5)34.4 (20.7 to 50.0)45.2 (29.7 to 60.1)50.0 (33.3 to 66.7)16.7 (8.3 to 30.8)33.3 (19.3 to 49.2)40.7 (24.8 to 58.3)
At Follow-up visit9.1 (3.4 to 20.2)30.0 (18.2 to 45.5)21.9 (12.1 to 36.2)19.4 (8.8 to 32.7)21.4 (9.8 to 36.6)20.0 (9.1 to 33.9)20.0 (9.1 to 33.9)7.4 (2.0 to 20.4)
Statistical analysis
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.2450 · Risk difference (rd): 3.3 · 90% CI -5.4 to 14.9
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.2575 · Risk difference (rd): 3.1 · 90% CI -5.3 to 14.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0087 · Risk difference (rd): 16.1 · 90% CI 5.7 to 31.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0392 · Risk difference (rd): 10.7 · 90% CI 0.8 to 25.4
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 1.0000 · Risk difference (rd): 0.0 · 90% CI -11.2 to 11.2
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.1528 · Risk difference (rd): 7.8 · 90% CI -4.9 to 22.5
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.4989 · Risk difference (rd): 0.9 · 90% CI -12.7 to 15.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.5419 · Risk difference (rd): 0.3 · 90% CI -13.6 to 14.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.1362 · Risk difference (rd): 10.3 · 90% CI -5.0 to 26.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0541 · Risk difference (rd): 15.9 · 90% CI -0.4 to 33.9
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.3945 · Risk difference (rd): 3.3 · 90% CI -12.0 to 19.5
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0201 · Risk difference (rd): 23.3 · 90% CI 3.9 to 41.8
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.1372 · Risk difference (rd): 11.2 · 90% CI -5.4 to 28.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.3924 · Risk difference (rd): 3.5 · 90% CI -11.6 to 19.1
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0311 · Risk difference (rd): 20.1 · 90% CI 2.4 to 38.3
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0392 · Risk difference (rd): 20.0 · 90% CI 0.8 to 38.1
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.1541 · Risk difference (rd): 10.0 · 90% CI -6.2 to 26.4
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0091 · Risk difference (rd): 27.0 · 90% CI 6.8 to 45.4
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.2835 · Risk difference (rd): 8.5 · 90% CI -9.5 to 27.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.2700 · Risk difference (rd): 9.9 · 90% CI -8.7 to 27.8
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0662 · Risk difference (rd): 17.3 · 90% CI -1.4 to 36.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0050 · Risk difference (rd): 31.8 · 90% CI 9.2 to 50.4
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.0302 · Risk difference (rd): 20.0 · 90% CI 2.2 to 38.3
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0091 · Risk difference (rd): 27.0 · 90% CI 6.8 to 45.4
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.1561 · Risk difference (rd): 11.8 · 90% CI -6.5 to 30.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.0753 · Risk difference (rd): 16.2 · 90% CI -2.7 to 34.8
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0108 · Risk difference (rd): 27.0 · 90% CI 5.7 to 46.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0050 · Risk difference (rd): 31.8 · 90% CI 9.2 to 50.4
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.0775 · Risk difference (rd): 16.7 · 90% CI -2.9 to 35.7
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0243 · Risk difference (rd): 24.1 · 90% CI 3.4 to 43.4
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.0234 · Risk difference (rd): 20.9 · 90% CI 3.5 to 38.8
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.1134 · Risk difference (rd): 12.8 · 90% CI -2.8 to 29.3
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.1362 · Risk difference (rd): 10.3 · 90% CI -5.0 to 26.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.1029 · Risk difference (rd): 12.3 · 90% CI -3.4 to 29.8
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 1.0000 · Risk difference (rd): 0.0 · 90% CI -17.9 to 17.9
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.8972 · Risk difference (rd): -12.6 · 90% CI -28.8 to 3.5
SecondaryPercent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit

4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit
Percent changeVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
At Week 1-2.4 (-12.2 to 7.4)-2.9 (-12.5 to 6.8)-16.2 (-26.2 to -6.2)-19.9 (-29.6 to -10.2)-23.0 (-32.8 to -13.1)8.5 (-8.3 to 25.3)-16.5 (-32.9 to -0.1)-17.0 (-33.5 to -0.5)
At Week 2-15.3 (-28.0 to -2.6)-7.2 (-20.2 to 5.8)-38.1 (-51.0 to -25.2)-43.6 (-56.5 to -30.8)-39.0 (-52.1 to -26.0)-2.5 (-14.0 to 9.1)-34.2 (-45.4 to -22.9)-43.1 (-54.5 to -31.6)
At Week 3-17.1 (-31.0 to -3.1)-13.1 (-27.4 to 1.1)-50.6 (-64.4 to -36.7)-55.9 (-69.7 to -42.0)-49.2 (-63.2 to -35.1)-25.2 (-39.2 to -11.1)-39.8 (-53.0 to -26.6)-44.0 (-57.1 to -30.9)
At Week 4-25.9 (-39.8 to -12.0)-20.1 (-34.4 to -5.7)-55.8 (-69.5 to -42.1)-57.9 (-71.7 to -44.0)-56.7 (-70.8 to -42.7)-34.7 (-46.1 to -23.3)-46.4 (-56.9 to -35.9)-57.7 (-68.2 to -47.2)
At Week 6-21.6 (-38.0 to -5.3)-39.4 (-56.1 to -22.7)-59.4 (-75.4 to -43.5)-63.6 (-79.5 to -47.6)-60.3 (-76.4 to -44.1)-31.2 (-42.5 to -20.0)-48.9 (-59.3 to -38.6)-65.0 (-75.3 to -54.7)
At Follow-up visit-23.6 (-39.5 to -7.6)-24.5 (-41.0 to -8.0)-42.7 (-58.1 to -27.2)-37.0 (-52.6 to -21.4)-55.2 (-71.8 to -38.6)-26.3 (-47.5 to -5.2)-31.6 (-52.0 to -11.3)-24.6 (-45.2 to -4.1)
Statistical analysis
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Mixed Model Repeated Measure · p = 0.4781 · Ls mean difference: -0.5 · 90% CI -14.2 to 13.3
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Mixed Model Repeated Measure · p = 0.0522 · Ls mean difference: -13.8 · 90% CI -27.8 to 0.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Mixed Model Repeated Measure · p = 0.0187 · Ls mean difference: -17.5 · 90% CI -31.4 to -3.7
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Mixed Model Repeated Measure · p = 0.0080 · Ls mean difference: -20.6 · 90% CI -34.5 to -6.6
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Mixed Model Repeated Measure · p = 0.0401 · Ls mean difference: -25.0 · 90% CI -48.6 to -1.5
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Mixed Model Repeated Measure · p = 0.0379 · Ls mean difference: -25.5 · 90% CI -49.2 to -1.9
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Mixed Model Repeated Measure · p = 0.7678 · Ls mean difference: 8.1 · 90% CI -10.1 to 26.3
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Mixed Model Repeated Measure · p = 0.0193 · Ls mean difference: -22.8 · 90% CI -40.9 to -4.7
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Mixed Model Repeated Measure · p = 0.0052 · Ls mean difference: -28.3 · 90% CI -46.5 to -10.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Mixed Model Repeated Measure · p = 0.0164 · Ls mean difference: -23.7 · 90% CI -42.0 to -5.5
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Mixed Model Repeated Measure · p = 0.0008 · Ls mean difference: -31.7 · 90% CI -47.8 to -15.6
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Mixed Model Repeated Measure · p = <0.0001 · Ls mean difference: -40.6 · 90% CI -57.0 to -24.3
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Mixed Model Repeated Measure · p = 0.6269 · Ls mean difference: 3.9 · 90% CI -16.1 to 23.9
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Mixed Model Repeated Measure · p = 0.0027 · Ls mean difference: -33.5 · 90% CI -53.1 to -13.8
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Mixed Model Repeated Measure · p = 0.0007 · Ls mean difference: -38.8 · 90% CI -58.5 to -19.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Mixed Model Repeated Measure · p = 0.0041 · Ls mean difference: -32.1 · 90% CI -51.9 to -12.3
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Mixed Model Repeated Measure · p = 0.1054 · Ls mean difference: -14.6 · 90% CI -33.9 to 4.6
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Mixed Model Repeated Measure · p = 0.0542 · Ls mean difference: -18.8 · 90% CI -38.1 to 0.5
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Mixed Model Repeated Measure · p = 0.6847 · Ls mean difference: 5.8 · 90% CI -14.2 to 25.9
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Mixed Model Repeated Measure · p = 0.0062 · Ls mean difference: -29.9 · 90% CI -49.4 to -10.3
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Mixed Model Repeated Measure · p = 0.0040 · Ls mean difference: -32.0 · 90% CI -51.6 to -12.3
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Mixed Model Repeated Measure · p = 0.0054 · Ls mean difference: -30.8 · 90% CI -50.6 to -11.0
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Mixed Model Repeated Measure · p = 0.1076 · Ls mean difference: -11.7 · 90% CI -27.2 to 3.9
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Mixed Model Repeated Measure · p = 0.0082 · Ls mean difference: -23.0 · 90% CI -38.6 to -7.3
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Mixed Model Repeated Measure · p = 0.1051 · Ls mean difference: -17.8 · 90% CI -41.2 to 5.6
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Mixed Model Repeated Measure · p = 0.0034 · Ls mean difference: -37.8 · 90% CI -60.6 to -15.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Mixed Model Repeated Measure · p = 0.0014 · Ls mean difference: -41.9 · 90% CI -64.8 to -19.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Mixed Model Repeated Measure · p = 0.0030 · Ls mean difference: -38.6 · 90% CI -61.6 to -15.6
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Mixed Model Repeated Measure · p = 0.0289 · Ls mean difference: -17.7 · 90% CI -33.0 to -2.4
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Mixed Model Repeated Measure · p = 0.0002 · Ls mean difference: -33.8 · 90% CI -49.2 to -18.4
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Mixed Model Repeated Measure · p = 0.4739 · Ls mean difference: -0.9 · 90% CI -23.9 to 22.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Mixed Model Repeated Measure · p = 0.0789 · Ls mean difference: -19.1 · 90% CI -41.3 to 3.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Mixed Model Repeated Measure · p = 0.1611 · Ls mean difference: -13.4 · 90% CI -35.7 to 8.9
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Mixed Model Repeated Measure · p = 0.0124 · Ls mean difference: -31.6 · 90% CI -54.7 to -8.5
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Mixed Model Repeated Measure · p = 0.3828 · Ls mean difference: -5.3 · 90% CI -34.7 to 24.1
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Mixed Model Repeated Measure · p = 0.5383 · Ls mean difference: 1.7 · 90% CI -27.9 to 31.3
SecondaryPercentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation

EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

Time frame:
Baseline, Weeks 1, 2, 3, 4 and 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation
Percentage of participantsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
At Week 15.4 (1.4 to 15.5)0.0 (0.0 to 7.3)19.4 (10.7 to 32.8)5.4 (1.4 to 15.5)16.7 (7.5 to 30.2)0.0 (0.0 to 7.5)13.9 (6.9 to 25.4)21.6 (11.2 to 34.3)
At Week 28.1 (3.0 to 18.5)10.8 (4.8 to 22.2)27.8 (15.9 to 40.9)24.3 (14.5 to 37.0)38.9 (25.4 to 53.0)13.9 (6.9 to 25.4)25.0 (14.9 to 38.0)32.4 (20.6 to 46.4)
At Week 35.4 (1.4 to 15.5)16.2 (7.3 to 29.3)36.1 (22.9 to 50.0)43.2 (29.3 to 56.8)41.7 (29.0 to 56.0)19.4 (10.7 to 32.8)19.4 (10.7 to 32.8)43.2 (29.3 to 56.8)
At Week 424.3 (14.5 to 37.0)21.6 (11.2 to 34.3)38.9 (25.4 to 53.0)43.2 (29.3 to 56.8)50.0 (35.3 to 64.7)22.2 (11.6 to 35.3)36.1 (22.9 to 50.0)48.6 (34.3 to 63.0)
At Week 635.1 (22.2 to 49.3)32.4 (20.6 to 46.4)52.8 (38.0 to 67.2)54.1 (40.2 to 68.2)50.0 (35.3 to 64.7)16.7 (7.5 to 30.2)36.1 (22.9 to 50.0)51.4 (37.0 to 65.7)
Statistical analysis
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.8964 · Risk difference (rd): -5.4 · 90% CI -16.1 to 2.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.0391 · Risk difference (rd): 14.0 · 90% CI 1.0 to 28.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 1.0000 · Risk difference (rd): 0.0 · 90% CI -10.8 to 10.8
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0708 · Risk difference (rd): 11.3 · 90% CI -1.4 to 25.0
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.0122 · Risk difference (rd): 13.9 · 90% CI 4.7 to 27.0
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0016 · Risk difference (rd): 21.6 · 90% CI 11.0 to 35.6
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.3950 · Risk difference (rd): 2.7 · 90% CI -9.8 to 16.1
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.0173 · Risk difference (rd): 19.7 · 90% CI 4.2 to 35.6
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0327 · Risk difference (rd): 16.2 · 90% CI 1.4 to 31.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0011 · Risk difference (rd): 30.8 · 90% CI 13.2 to 46.6
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.1348 · Risk difference (rd): 11.1 · 90% CI -5.0 to 27.2
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0328 · Risk difference (rd): 18.5 · 90% CI 1.5 to 34.8
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.0769 · Risk difference (rd): 10.8 · 90% CI -1.8 to 24.4
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.0005 · Risk difference (rd): 30.7 · 90% CI 13.2 to 46.0
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = <0.0001 · Risk difference (rd): 37.8 · 90% CI 22.1 to 53.1
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0001 · Risk difference (rd): 36.3 · 90% CI 19.7 to 51.8
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 1.0000 · Risk difference (rd): 0.0 · 90% CI -16.5 to 16.5
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0173 · Risk difference (rd): 23.8 · 90% CI 4.5 to 41.5
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.5663 · Risk difference (rd): -2.7 · 90% CI -19.9 to 14.2
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.1243 · Risk difference (rd): 14.6 · 90% CI -3.8 to 32.6
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0460 · Risk difference (rd): 18.9 · 90% CI -0.5 to 36.6
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.0130 · Risk difference (rd): 25.7 · 90% CI 4.8 to 43.3
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.1194 · Risk difference (rd): 13.9 · 90% CI -4.2 to 31.4
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0097 · Risk difference (rd): 26.4 · 90% CI 6.5 to 44.4
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.1% Cream QD · Chan and Zhang Exact Method · p = 0.5556 · Risk difference (rd): -2.7 · 90% CI -21.0 to 16.1
  • Vehicle Cream Once Daily (QD) vs PF-06700841 0.3% Cream QD · Chan and Zhang Exact Method · p = 0.0761 · Risk difference (rd): 17.6 · 90% CI -2.5 to 36.5
  • Vehicle Cream Once Daily (QD) vs PF-06700841 1.0% Cream QD · Chan and Zhang Exact Method · p = 0.0583 · Risk difference (rd): 18.9 · 90% CI -0.8 to 37.6
  • Vehicle Cream Once Daily (QD) vs PF-06700841 3.0% Cream QD · Chan and Zhang Exact Method · p = 0.1245 · Risk difference (rd): 14.9 · 90% CI -5.0 to 33.7
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 0.3% Cream BID · Chan and Zhang Exact Method · p = 0.0382 · Risk difference (rd): 19.4 · 90% CI 1.5 to 36.5
  • Vehicle Cream Twice Daily (BID) vs PF-06700841 1.0% Cream BID · Chan and Zhang Exact Method · p = 0.0011 · Risk difference (rd): 34.7 · 90% CI 13.2 to 51.4
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and all non-SAEs.

Time frame:
Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
TEAEs181711121017914
SAEs00000000
SecondaryNumber of Participants With Pre-defined Criteria For Vital Signs

Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) sitting DBP: change of \>= 20 millimeter of mercury (mmHg) increase, b) sitting DBP: change of \>=20mmHg decrease, c) supine DBP: less than (\<) 50 mmHg, d) supine DBP: change of \>= 20mmHg increase, e) supine DBP: change of \>= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) sitting SBP: \<90 mmHg, b) sitting SBP: change of \>=30mmHg increase, c) sitting SBP: change of \>=30mmHg decrease, d) supine SBP: change of \>=30mmHg increase, e) supine SBP: change of \>=30mmHg decrease and f) Supine SBP: value \<90mmHg.

Time frame:
Baseline up to Week 6
Reported as:
Count of participants · Participants
Number of Participants With Pre-defined Criteria For Vital Signs
ParticipantsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Sitting DBP: Change >= 20 mm Hg increase00120000
Sitting DBP: Change >= 20mmHg decrease10010100
Supine DBP: Value <50 mmHg00000100
Supine DBP: Change >= 20mmHg increase01121010
Supine DBP: Change >= 20mmHg decrease00000010
Sitting SBP: <90mmHg00010000
Sitting SBP: change >= 30mmHg increase00010001
Sitting SBP: change >= 30mmHg decrease00001000
Supine SBP: Change >= 30mmHg increase10100110
Supine SBP: Change >= 30mmHg decrease00100020
Supine SBP: Value <90mmHg01100000
SecondaryNumber of Participants With Laboratory Abnormalities

Hemoglobin (HGB),hematocrit,erythrocytes (ery.),HDL cholesterol (chl.)\<0.8\*lower limit of normal(LLN);reticulocytes (ret.), ret./ery. (%)\<0.5\*LLN,\>1.5\*upper limit of normal (ULN);ery. mean corpuscular (EMC) volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leukocytes (leu.),glucose\<0.6\*LLN,\>1.5\*ULN;lymphocytes (lym.), lym./leu.(%), neutrophils (neu.), neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;basophils (bas.), bas./leu.(%), eosinophils (eos.), eos./leu., monocytes (mon.), mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20.

Time frame:
Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Number of Participants With Laboratory Abnormalities2622232216212424
SecondaryNumber of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings

Clinically significant ECG criteria included PR interval: value greater than (\>) 280 millisecond (msec), percentage change greater than equal to (\>=) 25/50 percentage, QRS interval: value \>120 msec, percentage change \>= 50% and QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30\<=change\<60.

Time frame:
Baseline up to Week 6
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings
ParticipantsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
PR interval : value >280 msec00001000
PR interval : %change>=25/50%01101020
QRS interval: value >120 msec00000011
QRS interval: %Change>=50%00000100
QTCF: 450 msec00110100
QTCF: 30<=Change<6001111210
SecondaryChange From Baseline in Clinical Chemistry-Lactate Dehydrogenase Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame:
Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Reported as:
Mean · Units per liter
Change From Baseline in Clinical Chemistry-Lactate Dehydrogenase Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Units per literVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Change at week 10.4 ± 25.99-7.4 ± 30.20-5.3 ± 16.99-9.3 ± 22.65-18.4 ± 33.42-8.0 ± 34.51-8.0 ± 19.37-4.3 ± 29.08
Change at week 2-8.8 ± 21.56-7.8 ± 27.99-1.9 ± 18.18-8.8 ± 23.70-15.8 ± 42.19-0.3 ± 22.81-8.0 ± 22.31-4.9 ± 24.49
Change at week 4-8.6 ± 23.93-5.4 ± 22.87-9.3 ± 19.61-12.1 ± 28.54-16.3 ± 33.97-1.0 ± 29.29-19.5 ± 19.94-3.7 ± 24.96
Change at week 6-8.8 ± 18.25-8.1 ± 32.02-1.5 ± 32.42-6.4 ± 28.53-18.2 ± 33.86-9.7 ± 20.68-11.2 ± 22.34-7.0 ± 24.65
Change at follow-up visit-12.3 ± 24.82-12.0 ± 28.834.0 ± 43.45-2.7 ± 26.27-15.1 ± 38.23-11.3 ± 29.39-13.3 ± 25.370.2 ± 16.48
SecondaryChange From Baseline in Clinical Chemistry- Protein and Albumin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame:
Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Reported as:
Mean · Gram per deciliter
Change From Baseline in Clinical Chemistry- Protein and Albumin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Gram per deciliterVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Protein: change at week 1-0.01 ± 0.439-0.04 ± 0.294-0.14 ± 0.433-0.04 ± 0.264-0.03 ± 0.421-0.10 ± 0.360-0.01 ± 0.344-0.02 ± 0.301
Protein:change at week 2-0.09 ± 0.3830.03 ± 0.303-0.18 ± 0.402-0.01 ± 0.2750.01 ± 0.5610.02 ± 0.503-0.04 ± 0.286-0.10 ± 0.299
Protein: change at week 4-0.10 ± 0.3800.07 ± 0.315-0.08 ± 0.429-0.03 ± 0.341-0.04 ± 0.465-0.18 ± 0.292-0.15 ± 0.2420.03 ± 0.280
Protein: change at week 6-0.13 ± 0.4030.13 ± 0.379-0.19 ± 0.4520.01 ± 0.368-0.03 ± 0.405-0.10 ± 0.424-0.09 ± 0.368-0.09 ± 0.310
Protein: change at follow-up visit-0.07 ± 0.3410.05 ± 0.457-0.15 ± 0.481-0.04 ± 0.4040.03 ± 0.481-0.18 ± 0.471-0.09 ± 0.3980.02 ± 0.299
Albumin:change at week 1-0.04 ± 0.269-0.05 ± 0.205-0.10 ± 0.283-0.02 ± 0.1770.00 ± 0.256-0.05 ± 0.218-0.03 ± 0.2460.00 ± 0.169
Albumin:change at week 2-0.06 ± 0.2350.02 ± 0.201-0.10 ± 0.256-0.02 ± 0.204-0.01 ± 0.2830.02 ± 0.266-0.03 ± 0.174-0.06 ± 0.202
Albumin: change at week 4-0.08 ± 0.2450.07 ± 0.172-0.08 ± 0.2850.01 ± 0.2390.04 ± 0.292-0.10 ± 0.232-0.08 ± 0.1800.03 ± 0.224
Albumin:change at week 6-0.08 ± 0.2590.08 ± 0.245-0.14 ± 0.333-0.02 ± 0.269-0.00 ± 0.218-0.03 ± 0.252-0.07 ± 0.244-0.05 ± 0.227
Albumin: change at follow-up visit-0.06 ± 0.2470.10 ± 0.260-0.09 ± 0.277-0.04 ± 0.295-0.01 ± 0.346-0.09 ± 0.262-0.02 ± 0.2110.06 ± 0.181
SecondaryChange From Baseline in Clinical Chemistry- Urea Nitrogen, Urate, Calcium and Glucose Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame:
Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Reported as:
Mean · Microgram per deciliter
Change From Baseline in Clinical Chemistry- Urea Nitrogen, Urate, Calcium and Glucose Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Microgram per deciliterVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Urea nitrogen: change at week 10.9 ± 4.570.6 ± 3.040.1 ± 3.121.0 ± 3.191.0 ± 3.050.2 ± 2.190.4 ± 3.38-0.1 ± 2.65
Urea nitrogen: change at week 20.8 ± 3.890.0 ± 2.710.6 ± 3.540.9 ± 3.180.5 ± 3.630.6 ± 4.190.8 ± 2.990.4 ± 3.28
Urea nitrogen: change at week 40.6 ± 3.390.0 ± 3.04-0.0 ± 2.671.4 ± 3.060.5 ± 3.84-0.7 ± 2.961.3 ± 2.81-0.2 ± 3.61
Urea nitrogen: change at week 60.7 ± 2.84-0.2 ± 3.11-0.6 ± 3.610.9 ± 3.270.3 ± 3.82-0.8 ± 3.240.2 ± 3.52-0.4 ± 3.69
Urea nitrogen: change at follow-up visit0.0 ± 3.17-0.3 ± 3.130.4 ± 2.601.2 ± 4.220.2 ± 2.870.8 ± 3.780.5 ± 3.420.1 ± 3.78
Urate:change at week 10.16 ± 0.8070.01 ± 0.6060.16 ± 0.678-0.01 ± 0.5610.00 ± 0.7390.05 ± 0.661-0.02 ± 0.704-0.14 ± 0.890
Urate: change at week 20.30 ± 0.990-0.11 ± 0.6550.12 ± 0.617-0.03 ± 0.649-0.15 ± 0.8420.27 ± 1.025-0.03 ± 0.718-0.37 ± 1.059
Urate: change at week 40.21 ± 0.4970.14 ± 0.7310.06 ± 0.756-0.06 ± 0.621-0.14 ± 0.8560.22 ± 0.806-0.21 ± 0.663-0.16 ± 0.713
Urate: change at week 60.13 ± 0.7280.07 ± 0.984-0.02 ± 0.8310.06 ± 0.630-0.02 ± 0.6490.06 ± 0.534-0.11 ± 0.827-0.21 ± 1.084
Urate: change at follow- up visit-0.11 ± 0.721-0.33 ± 0.7530.05 ± 0.763-0.21 ± 0.554-0.02 ± 0.8100.02 ± 0.590-0.08 ± 0.677-0.20 ± 0.989
Calcium:change at week 10.01 ± 0.4190.01 ± 0.259-0.06 ± 0.377-0.02 ± 0.2480.07 ± 0.386-0.02 ± 0.303-0.01 ± 0.2950.09 ± 0.318
Calcium: change at week 2-0.08 ± 0.4170.00 ± 0.268-0.10 ± 0.3620.05 ± 0.2960.07 ± 0.4230.03 ± 0.389-0.10 ± 0.293-0.01 ± 0.244
Calcium: change at week 4-0.04 ± 0.3540.11 ± 0.329-0.07 ± 0.3450.05 ± 0.2720.00 ± 0.376-0.08 ± 0.309-0.03 ± 0.2570.10 ± 0.341
Calcium: change at week 6-0.04 ± 0.3550.10 ± 0.303-0.21 ± 0.3930.03 ± 0.3150.00 ± 0.397-0.05 ± 0.335-0.05 ± 0.464-0.04 ± 0.337
Calcium: change at follow-up visit0.00 ± 0.317-0.01 ± 0.345-0.08 ± 0.4090.00 ± 0.3230.10 ± 0.441-0.05 ± 0.4190.01 ± 0.3780.05 ± 0.356
Glucose:change at week 14.9 ± 8.735.7 ± 13.973.4 ± 14.624.5 ± 8.604.4 ± 16.144.5 ± 29.905.6 ± 13.143.3 ± 13.58
Glucose: change at week 29.7 ± 23.711.2 ± 17.340.6 ± 10.973.2 ± 12.633.1 ± 10.00-1.9 ± 13.517.9 ± 16.672.7 ± 18.07
Glucose: change at week 47.3 ± 15.600.5 ± 12.50-1.2 ± 15.864.5 ± 13.992.8 ± 20.201.3 ± 24.0110.7 ± 26.133.4 ± 18.33
Glucose: change at week 63.5 ± 9.192.4 ± 17.55-1.7 ± 10.622.1 ± 13.80-0.5 ± 9.77-3.4 ± 16.374.3 ± 12.231.5 ± 12.62
Glucose: change at follow -up visit4.5 ± 11.582.2 ± 11.454.8 ± 13.284.6 ± 14.776.0 ± 13.796.2 ± 16.759.1 ± 17.212.0 ± 22.43
SecondaryChange From Baseline in Clinical Chemistry- Sodium, Potassium, Chloride and Bicarbonate Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame:
Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Reported as:
Mean · Milliequivalents per liter
Change From Baseline in Clinical Chemistry- Sodium, Potassium, Chloride and Bicarbonate Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Milliequivalents per literVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Sodium: change at week 10.1 ± 2.34-0.0 ± 1.77-0.7 ± 2.04-0.6 ± 2.17-0.4 ± 3.500.4 ± 1.970.0 ± 2.08-0.1 ± 3.39
Sodium: change at week 2-0.5 ± 2.23-0.3 ± 1.89-0.1 ± 2.39-0.2 ± 2.18-0.4 ± 3.61-0.2 ± 2.61-0.5 ± 2.20-0.3 ± 3.45
Sodium:change at week 4-0.3 ± 2.700.6 ± 1.83-0.2 ± 2.44-0.7 ± 2.71-0.4 ± 3.08-0.4 ± 2.72-0.1 ± 1.77-0.3 ± 3.28
Sodium:change at week 6-0.8 ± 2.310.0 ± 2.39-0.2 ± 2.23-0.9 ± 2.40-0.9 ± 3.550.9 ± 2.50-0.1 ± 2.23-0.5 ± 2.49
Sodium: change at follow up-0.4 ± 3.260.5 ± 2.50-0.1 ± 2.45-0.3 ± 2.41-0.8 ± 3.590.7 ± 1.94-0.1 ± 2.460.1 ± 3.32
Potassium: change at week 1-0.00 ± 0.3630.08 ± 0.2820.03 ± 0.3720.02 ± 0.3470.07 ± 0.3430.01 ± 0.3370.00 ± 0.4290.20 ± 0.464
Potassium:change at week 2-0.14 ± 0.3670.04 ± 0.298-0.07 ± 0.3380.04 ± 0.3590.07 ± 0.3460.00 ± 0.245-0.16 ± 0.438-0.02 ± 0.322
Potassium: change at week 40.01 ± 0.389-0.06 ± 0.285-0.02 ± 0.350-0.01 ± 0.3270.05 ± 0.375-0.09 ± 0.300-0.03 ± 0.4150.26 ± 0.350
Potassium: change at week 6-0.09 ± 0.3730.03 ± 0.295-0.06 ± 0.3320.03 ± 0.407-0.06 ± 0.262-0.06 ± 0.309-0.10 ± 0.3550.09 ± 0.388
Potassium: change at follow-up visit-0.11 ± 0.3790.10 ± 0.3750.03 ± 0.3940.04 ± 0.3510.12 ± 0.3580.05 ± 0.293-0.09 ± 0.4750.26 ± 0.460
Chloride: change at week 10.1 ± 2.110.3 ± 1.860.3 ± 1.570.0 ± 2.540.0 ± 2.660.6 ± 2.110.5 ± 2.020.5 ± 2.83
Chloride: change at week 2-0.2 ± 2.52-0.2 ± 2.080.7 ± 2.030.2 ± 2.50-0.2 ± 2.870.4 ± 2.700.4 ± 2.150.2 ± 2.99
Chloride: change at week 40.3 ± 2.050.6 ± 1.890.2 ± 2.68-0.4 ± 2.23-0.3 ± 2.160.3 ± 3.281.0 ± 2.21-0.2 ± 2.57
Chloride:change at week 6-0.6 ± 1.980.1 ± 2.270.0 ± 2.34-0.5 ± 2.44-0.4 ± 3.050.5 ± 2.930.9 ± 2.730.0 ± 2.32
Chloride: change at follow-up visit0.6 ± 2.97-0.3 ± 2.160.8 ± 2.640.1 ± 2.41-0.4 ± 2.901.3 ± 2.110.3 ± 2.350.4 ± 3.16
Bicarbonate: change at week 10.13 ± 2.548-0.38 ± 1.759-0.20 ± 1.965-0.18 ± 1.7680.28 ± 1.6380.09 ± 2.209-0.21 ± 2.388-0.02 ± 1.651
Bicarbonate: change at week 20.08 ± 2.229-0.40 ± 2.151-0.51 ± 1.9560.10 ± 2.129-0.13 ± 1.931-0.15 ± 2.341-0.60 ± 2.354-0.07 ± 1.828
Bicarbonate: change at week 40.21 ± 2.7390.05 ± 2.128-0.24 ± 2.4840.34 ± 1.8680.02 ± 2.0110.14 ± 1.286-0.00 ± 2.6950.02 ± 1.704
Bicarbonate: change at week 60.52 ± 2.560-0.44 ± 2.5980.66 ± 2.1320.27 ± 2.2040.12 ± 2.4070.63 ± 2.096-0.19 ± 2.038-0.20 ± 2.217
Bicarbonate: change at follow-up visit-0.02 ± 2.9160.66 ± 2.2090.41 ± 2.0560.75 ± 2.3860.43 ± 2.1620.08 ± 1.6430.18 ± 2.3001.09 ± 2.049
SecondaryChange From Baseline in Hematology- Hemoglobin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame:
Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Reported as:
Mean · Gram per deciliter
Change From Baseline in Hematology- Hemoglobin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Gram per deciliterVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Change at week 1-0.01 ± 0.790-0.22 ± 0.620-0.36 ± 0.775-0.12 ± 0.678-0.26 ± 0.726-0.19 ± 0.698-0.21 ± 0.584-0.27 ± 0.679
Change at week 2-0.16 ± 0.636-0.09 ± 0.566-0.64 ± 0.715-0.24 ± 0.657-0.22 ± 0.798-0.16 ± 0.830-0.25 ± 0.625-0.32 ± 0.793
Change at week 40.03 ± 0.725-0.17 ± 0.630-0.48 ± 0.659-0.25 ± 0.628-0.06 ± 0.821-0.27 ± 0.789-0.32 ± 0.701-0.20 ± 0.658
Change at week 6-0.13 ± 0.832-0.06 ± 0.614-0.48 ± 0.767-0.03 ± 0.617-0.11 ± 0.775-0.22 ± 0.724-0.21 ± 0.833-0.28 ± 0.683
Change at follow-up visit0.05 ± 0.613-0.04 ± 0.717-0.49 ± 0.777-0.09 ± 0.7840.00 ± 0.773-0.27 ± 0.756-0.12 ± 0.826-0.18 ± 0.740
SecondaryChange From Baseline in Hematology - Hematocrit, Reticulocytes/Erythrocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes, Basophils/Leukocytes, Eosinophils/Leukocytes and Monocytes/Leukocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame:
Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Reported as:
Mean · Percentage of cells
Change From Baseline in Hematology - Hematocrit, Reticulocytes/Erythrocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes, Basophils/Leukocytes, Eosinophils/Leukocytes and Monocytes/Leukocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Percentage of cellsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Hematocrit: change at week 10.2 ± 2.51-0.8 ± 2.11-1.3 ± 2.61-0.4 ± 2.27-0.8 ± 2.41-0.5 ± 1.97-0.9 ± 2.04-0.9 ± 2.30
Hematocrit: change at week 2-0.5 ± 2.19-0.8 ± 2.12-1.8 ± 2.42-0.9 ± 2.32-0.7 ± 2.58-0.9 ± 2.55-0.7 ± 2.24-1.0 ± 2.61
Hematocrit: change at week 40.0 ± 2.45-0.8 ± 1.96-1.8 ± 2.06-0.8 ± 2.340.0 ± 2.73-1.0 ± 2.34-0.9 ± 2.29-0.5 ± 2.56
Hematocrit: change at week 6-0.6 ± 2.47-0.9 ± 1.93-1.6 ± 2.64-0.7 ± 2.23-0.6 ± 2.51-1.1 ± 1.98-1.1 ± 2.84-0.8 ± 2.60
Hematocrit: change at follow-up (FU) visit0.3 ± 2.49-0.7 ± 2.24-1.4 ± 3.05-0.7 ± 2.39-0.2 ± 2.50-0.6 ± 2.20-0.6 ± 2.73-0.3 ± 2.78
Reticulocytes/Erythrocytes change at week 10.03 ± 0.3170.14 ± 0.3780.02 ± 0.4830.06 ± 0.3640.11 ± 0.3180.01 ± 0.3200.04 ± 0.3550.01 ± 0.329
Reticulocytes/Erythrocytes: change at week 2-0.03 ± 0.3820.17 ± 0.3250.09 ± 0.413-0.02 ± 0.4730.19 ± 0.443-0.10 ± 0.3180.06 ± 0.315-0.01 ± 0.389
Reticulocytes/Erythrocytes: change at week 40.16 ± 0.596-0.08 ± 0.3590.01 ± 0.4600.19 ± 0.4290.10 ± 0.4090.03 ± 0.2900.04 ± 0.4460.05 ± 0.374
Reticulocytes/Erythrocytes: change at week 6-0.06 ± 0.3820.02 ± 0.3610.02 ± 0.4730.01 ± 0.4860.15 ± 0.399-0.15 ± 0.310-0.01 ± 0.3550.01 ± 0.463
Reticulocytes/Erythrocytes:change at FU visit-0.11 ± 0.396-0.02 ± 0.3840.10 ± 0.435-0.10 ± 0.398-0.03 ± 0.298-0.09 ± 0.331-0.19 ± 0.3950.11 ± 0.448
Lymphocytes/Leukocytes: change at week 1-0.43 ± 6.7720.68 ± 5.8142.33 ± 5.6160.06 ± 4.7651.31 ± 6.2590.59 ± 5.1790.49 ± 5.5091.79 ± 6.269
Lymphocytes/Leukocytes: change at week 20.20 ± 6.1750.84 ± 7.5441.68 ± 5.2081.50 ± 5.6390.23 ± 6.1750.50 ± 5.4050.72 ± 6.6380.86 ± 7.264
Lymphocytes/Leukocytes: change at week 41.58 ± 7.5910.51 ± 7.2971.43 ± 5.2980.43 ± 7.5862.41 ± 6.577-1.38 ± 5.4151.07 ± 5.7390.56 ± 7.264
Lymphocytes/Leukocytes: change at week 6-0.92 ± 6.701-0.06 ± 5.4610.82 ± 6.6851.28 ± 5.8811.65 ± 5.8180.50 ± 4.452-0.04 ± 5.3001.52 ± 7.266
Lymphocytes/Leukocytes: change at follow-up visit1.53 ± 6.2191.25 ± 4.9741.61 ± 6.597-0.85 ± 6.3671.34 ± 6.1650.22 ± 6.3150.07 ± 5.1032.48 ± 6.914
Neutrophils/Leukocytes: change at week 10.57 ± 7.515-0.95 ± 6.957-2.93 ± 6.1910.30 ± 5.755-0.96 ± 7.843-0.17 ± 5.769-1.87 ± 6.873-1.44 ± 6.580
Neutrophils/Leukocytes: change at week 2-0.12 ± 7.827-0.34 ± 8.219-1.70 ± 6.037-1.50 ± 6.578-0.24 ± 6.146-0.49 ± 6.665-1.04 ± 7.376-0.56 ± 8.017
Neutrophils/Leukocytes: change at week 4-1.42 ± 8.812-0.30 ± 7.754-1.52 ± 6.6610.06 ± 8.536-2.25 ± 7.4681.65 ± 6.622-1.42 ± 6.498-0.45 ± 7.362
Neutrophils/Leukocytes: change at week 60.95 ± 8.648-0.58 ± 7.009-0.64 ± 6.833-1.14 ± 6.872-1.15 ± 6.969-0.56 ± 5.6990.13 ± 6.029-1.01 ± 8.445
Neutrophils/Leukocytes: change at follow-up visit-1.71 ± 7.046-0.65 ± 6.057-1.86 ± 6.8921.32 ± 7.355-1.32 ± 6.559-0.41 ± 6.961-0.71 ± 6.590-2.04 ± 7.700
Basophils/Leukocytes: change at week 1-0.06 ± 0.431-0.02 ± 0.690-0.06 ± 0.5240.08 ± 0.3190.03 ± 0.515-0.03 ± 0.291-0.01 ± 0.411-0.01 ± 0.570
Basophils/Leukocytes: change at week 2-0.02 ± 0.3040.01 ± 0.493-0.09 ± 0.3420.02 ± 0.323-0.03 ± 0.5320.03 ± 0.355-0.06 ± 0.624-0.24 ± 0.709
Basophils/Leukocytes: change at week 4-0.07 ± 0.4850.06 ± 0.651-0.03 ± 0.4200.01 ± 0.402-0.08 ± 0.712-0.05 ± 0.362-0.01 ± 0.465-0.10 ± 0.464
Basophils/Leukocytes: change at week 6-0.07 ± 0.2720.11 ± 0.809-0.12 ± 0.4800.08 ± 0.458-0.16 ± 0.557-0.05 ± 0.296-0.12 ± 0.576-0.17 ± 0.750
Basophils/Leukocytes: change at follow-up visit-0.04 ± 0.360-0.15 ± 0.476-0.13 ± 0.4430.02 ± 0.512-0.25 ± 0.541-0.05 ± 0.4490.01 ± 0.472-0.25 ± 0.572
Eosinophils/Leukocytes: change at week 1-0.09 ± 1.3900.17 ± 1.8400.17 ± 0.934-0.37 ± 1.549-0.31 ± 1.607-0.19 ± 1.4100.89 ± 1.850-0.23 ± 1.339
Eosinophils/Leukocytes: change at week 2-0.11 ± 1.801-0.20 ± 1.298-0.16 ± 1.2840.11 ± 1.460-0.27 ± 1.131-0.14 ± 1.1990.16 ± 1.304-0.05 ± 1.531
Eosinophils/Leukocytes: change at week 40.42 ± 1.982-0.12 ± 1.7250.15 ± 1.884-0.37 ± 1.729-0.35 ± 1.431-0.34 ± 1.2580.40 ± 1.468-0.37 ± 1.747
Eosinophils/Leukocytes: change at week 6-0.03 ± 1.5220.22 ± 1.570-0.04 ± 1.2130.02 ± 2.126-0.15 ± 1.714-0.01 ± 1.7670.05 ± 1.229-0.19 ± 1.840
Eosinophils/Leukocytes: change at follow-up visit0.16 ± 1.754-0.24 ± 1.860-0.09 ± 1.155-0.41 ± 2.1880.12 ± 1.954-0.05 ± 2.8050.50 ± 1.986-0.13 ± 2.021
Monocytes/Leukocytes: change at week 10.02 ± 1.9130.12 ± 1.3910.50 ± 1.428-0.06 ± 1.409-0.01 ± 1.593-0.19 ± 1.0430.51 ± 1.275-0.11 ± 1.251
Monocytes/Leukocytes: change at week 20.04 ± 2.055-0.31 ± 1.5020.30 ± 1.522-0.13 ± 1.2670.38 ± 1.3620.11 ± 1.3180.22 ± 1.414-0.01 ± 1.755
Monocytes/Leukocytes : change at week 4-0.51 ± 2.509-0.17 ± 1.966-0.02 ± 2.072-0.10 ± 1.5820.22 ± 1.3230.14 ± 1.323-0.03 ± 1.0390.33 ± 1.695
Monocytes/Leukocytes : change at week 60.06 ± 2.4880.33 ± 2.257-0.00 ± 1.813-0.24 ± 1.217-0.12 ± 1.0300.13 ± 0.807-0.02 ± 1.324-0.16 ± 1.516
Monocytes/Leukocytes : change at follow-up visit0.06 ± 2.105-0.22 ± 1.3040.50 ± 1.463-0.07 ± 1.2260.13 ± 1.2050.26 ± 1.5430.15 ± 1.599-0.04 ± 1.047
SecondaryChange From Baseline in Hematology- Erythrocytes and Reticulocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame:
Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Reported as:
Mean · 10^12*cells per liter
Change From Baseline in Hematology- Erythrocytes and Reticulocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
10^12*cells per literVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Erythrocytes: change at week 10.03 ± 0.261-0.07 ± 0.232-0.12 ± 0.264-0.04 ± 0.252-0.08 ± 0.254-0.08 ± 0.298-0.08 ± 0.192-0.09 ± 0.240
Erythrocytes: change at week 2-0.05 ± 0.234-0.03 ± 0.212-0.18 ± 0.251-0.10 ± 0.208-0.07 ± 0.242-0.10 ± 0.366-0.06 ± 0.229-0.11 ± 0.232
Erythrocytes: change at week 4-0.01 ± 0.216-0.05 ± 0.221-0.16 ± 0.251-0.10 ± 0.2330.01 ± 0.275-0.12 ± 0.271-0.08 ± 0.248-0.06 ± 0.219
Erythrocytes: change at week 6-0.04 ± 0.247-0.01 ± 0.180-0.17 ± 0.265-0.04 ± 0.238-0.02 ± 0.262-0.10 ± 0.256-0.07 ± 0.303-0.08 ± 0.239
Erythrocytes: change at follow-up visit0.03 ± 0.2200.02 ± 0.244-0.15 ± 0.266-0.03 ± 0.2540.04 ± 0.300-0.08 ± 0.280-0.03 ± 0.308-0.05 ± 0.262
Reticulocytes: change at week 10.0 ± 0.020.0 ± 0.02-0.0 ± 0.020.0 ± 0.020.0 ± 0.020.0 ± 0.010.0 ± 0.02-0.0 ± 0.02
Reticulocytes: change at week 2-0.0 ± 0.020.0 ± 0.020.0 ± 0.02-0.0 ± 0.020.0 ± 0.02-0.0 ± 0.020.0 ± 0.02-0.0 ± 0.02
Reticulocytes: change at week 40.0 ± 0.03-0.0 ± 0.02-0.0 ± 0.020.0 ± 0.020.0 ± 0.02-0.0 ± 0.01-0.0 ± 0.020.0 ± 0.02
Reticulocytes: change at week 6-0.0 ± 0.020.0 ± 0.020.0 ± 0.02-0.0 ± 0.020.0 ± 0.02-0.0 ± 0.01-0.0 ± 0.020.0 ± 0.02
Reticulocytes: change at follow-up visit-0.0 ± 0.02-0.0 ± 0.020.0 ± 0.02-0.0 ± 0.02-0.0 ± 0.01-0.0 ± 0.02-0.0 ± 0.020.0 ± 0.02
SecondaryChange From Baseline in Hematology- Platelets, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils and Monocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
Time frame:
Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)
Reported as:
Mean · 10^9 *cells per liter
Change From Baseline in Hematology- Platelets, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils and Monocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit
10^9 *cells per literVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Platelets: change at week 10.9 ± 60.036.8 ± 34.08-3.3 ± 32.391.0 ± 25.768.5 ± 41.616.6 ± 33.40-2.1 ± 31.9412.6 ± 44.08
Platelets: change at week 2-4.9 ± 58.167.1 ± 43.34-8.1 ± 41.92-0.1 ± 32.455.0 ± 31.39-4.9 ± 31.847.5 ± 37.9414.8 ± 50.99
Platelets: change at week 410.5 ± 36.4210.1 ± 37.55-2.4 ± 37.68-0.3 ± 36.27-5.9 ± 37.474.4 ± 37.790.7 ± 36.5111.0 ± 46.26
Platelets: change at week 64.9 ± 35.17-3.3 ± 32.76-6.6 ± 41.66-2.3 ± 32.70-5.2 ± 38.530.2 ± 37.28-1.8 ± 37.058.6 ± 47.85
Platelets: change at follow-up visit1.3 ± 30.4816.3 ± 37.13-8.5 ± 30.150.1 ± 32.3610.2 ± 47.30-5.2 ± 40.705.8 ± 48.552.5 ± 58.75
Leukocytes: change at week 10.027 ± 1.87400.395 ± 1.0940-0.051 ± 1.24030.407 ± 1.22250.259 ± 1.12900.068 ± 1.29290.238 ± 1.4993-0.025 ± 2.3529
Leukocytes: change at week 2-0.206 ± 1.88860.459 ± 1.5567-0.288 ± 1.6842-0.094 ± 1.2877-0.116 ± 1.0364-0.007 ± 1.26370.422 ± 1.8986-0.006 ± 2.3428
Leukocytes: change at week 4-0.203 ± 1.73900.729 ± 1.31990.189 ± 1.35340.085 ± 1.3541-0.074 ± 1.06410.398 ± 1.59990.168 ± 1.09020.041 ± 2.1647
Leukocytes: change at week 60.160 ± 1.70590.066 ± 1.0672-0.505 ± 1.64740.237 ± 1.4501-0.244 ± 1.2763-0.269 ± 1.0761-0.048 ± 1.3823-0.347 ± 2.1442
Leukocytes: change at follow-up visit-0.066 ± 1.57440.479 ± 1.0939-0.048 ± 2.02060.329 ± 1.39380.123 ± 0.8496-0.117 ± 1.48560.210 ± 1.7456-0.404 ± 2.4817
Lymphocytes: change at week 1-0.008 ± 0.55390.124 ± 0.36590.107 ± 0.31300.081 ± 0.38390.186 ± 0.38400.051 ± 0.35570.089 ± 0.43200.223 ± 0.3849
Lymphocytes: change at week 2-0.061 ± 0.55580.145 ± 0.37350.010 ± 0.41150.044 ± 0.42250.012 ± 0.4251-0.003 ± 0.31650.070 ± 0.46030.169 ± 0.5319
Lymphocytes: change at week 40.107 ± 0.43020.229 ± 0.39980.135 ± 0.44000.012 ± 0.45960.139 ± 0.39770.039 ± 0.41690.127 ± 0.26300.176 ± 0.6274
Lymphocytes: change at week 60.033 ± 0.33750.016 ± 0.3437-0.079 ± 0.48260.104 ± 0.43370.068 ± 0.3168-0.033 ± 0.30920.027 ± 0.24550.079 ± 0.3846
Lymphocytes: change at follow-up visit0.134 ± 0.32560.194 ± 0.35330.065 ± 0.6042-0.022 ± 0.44190.130 ± 0.4277-0.035 ± 0.40540.050 ± 0.46990.195 ± 0.4663
Neutrophils: change at week 10.027 ± 1.61370.205 ± 0.9185-0.177 ± 1.08050.319 ± 1.02760.069 ± 1.07060.017 ± 1.12910.030 ± 1.3015-0.251 ± 2.2421
Neutrophils: change at week 2-0.119 ± 1.56720.293 ± 1.5459-0.261 ± 1.3969-0.136 ± 1.0669-0.109 ± 0.9653-0.015 ± 1.13050.288 ± 1.7822-0.190 ± 2.0749
Neutrophils: change at week 4-0.304 ± 1.61170.441 ± 1.28140.036 ± 1.15950.096 ± 1.3199-0.190 ± 1.04040.338 ± 1.3577-0.005 ± 0.9958-0.158 ± 2.0005
Neutrophils: change at week 60.112 ± 1.6282-0.001 ± 0.8996-0.362 ± 1.31540.112 ± 1.2240-0.250 ± 1.1720-0.228 ± 0.9681-0.064 ± 1.2422-0.376 ± 2.1125
Neutrophils: change at follow-up visit-0.229 ± 1.33790.261 ± 0.8874-0.114 ± 1.45450.343 ± 1.3049-0.020 ± 0.7731-0.093 ± 1.23400.088 ± 1.4614-0.562 ± 2.3227
Basophils: change at week 1-0.006 ± 0.03190.004 ± 0.0445-0.007 ± 0.03490.010 ± 0.02580.003 ± 0.03610.001 ± 0.01910.002 ± 0.02990.002 ± 0.0343
Basophils: change at week 2-0.002 ± 0.01790.004 ± 0.0261-0.009 ± 0.02760.001 ± 0.0197-0.005 ± 0.03940.003 ± 0.0244-0.003 ± 0.0433-0.012 ± 0.0428
Basophils: change at week 4-0.006 ± 0.03280.011 ± 0.0404-0.002 ± 0.03000.001 ± 0.0256-0.007 ± 0.0495-0.001 ± 0.0255-0.001 ± 0.0337-0.004 ± 0.0323
Basophils: change at week 6-0.005 ± 0.01860.009 ± 0.0489-0.012 ± 0.03130.008 ± 0.0344-0.015 ± 0.0415-0.004 ± 0.0188-0.009 ± 0.0373-0.015 ± 0.0383
Basophils: change at follow-up visit-0.004 ± 0.0265-0.003 ± 0.0259-0.007 ± 0.03210.007 ± 0.0407-0.015 ± 0.0426-0.005 ± 0.02690.001 ± 0.0295-0.019 ± 0.0361
Eosinophils: change at week 10.007 ± 0.09640.036 ± 0.0963-0.004 ± 0.1092-0.011 ± 0.0930-0.014 ± 0.1216-0.008 ± 0.11480.068 ± 0.0959-0.006 ± 0.1165
Eosinophils: change at week 2-0.019 ± 0.1087-0.000 ± 0.0734-0.023 ± 0.08090.009 ± 0.0980-0.029 ± 0.0915-0.006 ± 0.06210.022 ± 0.07620.005 ± 0.1256
Eosinophils: change at week 40.032 ± 0.18130.018 ± 0.11200.008 ± 0.1325-0.019 ± 0.1102-0.032 ± 0.1040-0.012 ± 0.08320.042 ± 0.1076-0.012 ± 0.1499
Eosinophils: change at week 60.002 ± 0.09350.029 ± 0.1090-0.025 ± 0.13510.018 ± 0.1387-0.027 ± 0.1125-0.007 ± 0.1025-0.001 ± 0.0812-0.022 ± 0.1415
Eosinophils: change at follow-up visit0.022 ± 0.14610.006 ± 0.0931-0.023 ± 0.1196-0.004 ± 0.18100.008 ± 0.1270-0.008 ± 0.24830.048 ± 0.1520-0.011 ± 0.1945
Monocytes: change at week 10.006 ± 0.17960.030 ± 0.08550.030 ± 0.09870.009 ± 0.08790.019 ± 0.10550.006 ± 0.08770.051 ± 0.12440.011 ± 0.1195
Monocytes: change at week 2-0.006 ± 0.15090.016 ± 0.1343-0.003 ± 0.0724-0.014 ± 0.10550.017 ± 0.08650.013 ± 0.09830.049 ± 0.14710.025 ± 0.1496
Monocytes: change at week 4-0.035 ± 0.19040.030 ± 0.12120.013 ± 0.1234-0.003 ± 0.10920.009 ± 0.09860.035 ± 0.09780.007 ± 0.10080.038 ± 0.1331
Monocytes: change at week 60.017 ± 0.17770.017 ± 0.1069-0.025 ± 0.1191-0.005 ± 0.1021-0.019 ± 0.07260.004 ± 0.08470.003 ± 0.1097-0.012 ± 0.1200
Monocytes: change at follow-up visit0.011 ± 0.18060.021 ± 0.08240.030 ± 0.14670.005 ± 0.08870.021 ± 0.07390.018 ± 0.10470.029 ± 0.1788-0.006 ± 0.1282
SecondaryChange From Baseline in Lipids Profile Values at Week 6

Lipid parameters that were assessed: high density lipoprotein (HDL) cholesterol, triglycerides, cholesterol, low density lipoprotein (LDL) cholesterol.

Time frame:
Baseline, Week 6
Reported as:
Mean · Microgram per deciliter
Change From Baseline in Lipids Profile Values at Week 6
Microgram per deciliterVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
HDL cholesterol-2.8 ± 6.650.1 ± 5.34-1.3 ± 7.742.7 ± 8.331.9 ± 11.180.0 ± 6.761.2 ± 4.120.3 ± 8.56
Triglycerides3.3 ± 38.84-4.2 ± 59.30-6.5 ± 37.301.8 ± 60.74-18.9 ± 56.78-8.1 ± 50.41-7.0 ± 58.36-4.4 ± 55.66
Cholesterol-3.5 ± 16.39-5.6 ± 27.59-12.8 ± 20.536.8 ± 24.09-10.4 ± 30.79-0.2 ± 18.705.3 ± 30.58-0.9 ± 19.86
LDL Cholesterol-3.4 ± 14.45-6.3 ± 25.28-12.1 ± 16.442.1 ± 20.13-11.0 ± 29.06-0.8 ± 14.484.4 ± 23.55-1.1 ± 16.29
SecondaryChange From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 6

Mean change in total cholesterol/HDL cholesterol ratio was assessed and reported.

Time frame:
Baseline, Week 6
Reported as:
Mean · Ratio
Change From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 6
RatioVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Change From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 60.0 ± 0.31-0.1 ± 0.48-0.2 ± 0.40-0.0 ± 0.32-0.3 ± 0.77-0.0 ± 0.350.0 ± 0.46-0.0 ± 0.42
SecondaryChange From Baseline in Electrocardiogram (ECG) Parameter- Heart Rate at Weeks 2 and 6
Time frame:
Baseline, Weeks 2 and 6
Reported as:
Mean · Beats per minute
Change From Baseline in Electrocardiogram (ECG) Parameter- Heart Rate at Weeks 2 and 6
Beats per minuteVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Baseline66.8 ± 11.4566.9 ± 9.3368.4 ± 14.6664.9 ± 9.0564.9 ± 12.2666.9 ± 12.0368.2 ± 12.1168.1 ± 12.48
Change at week 20.7 ± 10.05-0.5 ± 8.03-1.8 ± 11.53-0.6 ± 7.881.9 ± 8.012.2 ± 8.761.7 ± 9.131.7 ± 12.52
Change at week 60.3 ± 6.19-1.1 ± 7.65-1.7 ± 9.060.8 ± 8.53-0.3 ± 8.46-0.8 ± 8.230.5 ± 8.76-0.4 ± 12.06
SecondaryChange From Baseline in PR, QRS, QTCF and QT Interval at Weeks 2 and 6
Time frame:
Baseline, Weeks 2 and 6
Reported as:
Mean · Milliseconds
Change From Baseline in PR, QRS, QTCF and QT Interval at Weeks 2 and 6
MillisecondsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
PR interval: baseline161.9 ± 23.30160.2 ± 24.01161.4 ± 27.59162.5 ± 22.04160.7 ± 24.20156.4 ± 22.65157.9 ± 23.55157.8 ± 23.15
PR interval: change at week 20.8 ± 14.41-0.9 ± 15.920.7 ± 18.540.3 ± 10.131.1 ± 14.426.0 ± 14.791.2 ± 16.062.1 ± 7.98
PR interval: change at week 6-0.9 ± 10.16-0.1 ± 13.812.8 ± 19.662.9 ± 13.633.5 ± 21.884.0 ± 14.566.5 ± 19.155.7 ± 16.11
QRS interval: baseline92.5 ± 9.3691.5 ± 9.7191.1 ± 9.2993.0 ± 11.1393.1 ± 8.6992.2 ± 13.0092.4 ± 13.3091.5 ± 11.68
QRS interval: change at week 2-1.4 ± 8.02-0.4 ± 5.34-1.3 ± 3.46-0.8 ± 5.640.1 ± 4.791.5 ± 9.290.2 ± 8.071.0 ± 5.63
QRS interval: change at week 6-1.9 ± 6.551.4 ± 5.62-0.5 ± 4.76-0.9 ± 4.04-1.3 ± 4.000.9 ± 6.370.6 ± 5.490.7 ± 5.67
QTCF interval: baseline407.7 ± 17.78397.9 ± 15.98403.8 ± 22.43408.5 ± 18.42401.0 ± 16.29403.0 ± 16.65397.7 ± 17.05405.0 ± 20.38
QTCF interval: change at week 2-5.7 ± 11.86-1.5 ± 13.70-3.9 ± 15.602.6 ± 16.20-0.6 ± 12.751.4 ± 15.562.4 ± 10.32-4.6 ± 15.43
QTCF interval: change at week 6-4.1 ± 14.61-0.5 ± 14.93-1.9 ± 14.370.3 ± 17.19-1.4 ± 14.934.6 ± 14.272.0 ± 11.94-0.2 ± 9.67
QT interval: baseline395.2 ± 31.53385.3 ± 23.64388.8 ± 33.66401.0 ± 25.23392.0 ± 27.36390.9 ± 24.87383.8 ± 30.79390.6 ± 32.43
QT interval: change at week 2-5.9 ± 23.16-1.3 ± 17.73-1.1 ± 19.313.5 ± 21.06-4.5 ± 15.751.2 ± 24.03-2.3 ± 18.69-4.6 ± 25.76
QT interval: change at week 6-4.9 ± 19.541.3 ± 18.110.9 ± 16.11-4.1 ± 23.42-0.9 ± 20.127.8 ± 24.11-1.4 ± 20.474.0 ± 27.74
SecondaryChange From Baseline in Vital Signs- Blood Pressure (BP) at Weeks 2 and 6

Blood pressure included supine and sitting systolic and diastolic BP.

Time frame:
Baseline, Weeks 2 and 6
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Vital Signs- Blood Pressure (BP) at Weeks 2 and 6
Millimeters of mercuryVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Supine systolic BP: Baseline123.3 ± 12.01123.2 ± 12.35123.0 ± 13.89119.7 ± 9.08122.6 ± 12.76123.1 ± 12.40117.1 ± 14.07118.9 ± 12.43
Supine systolic BP: change at week 20.3 ± 11.55-1.4 ± 9.610.5 ± 14.732.3 ± 6.99-0.3 ± 10.25-0.3 ± 8.023.5 ± 13.652.9 ± 8.48
Supine systolic BP: change at week 6-0.2 ± 12.981.1 ± 10.062.0 ± 14.050.2 ± 9.13-3.4 ± 11.02-1.4 ± 10.492.1 ± 12.410.6 ± 10.31
Sitting systolic BP: Baseline117.7 ± 13.05120.8 ± 10.26120.2 ± 12.43116.9 ± 17.76124.6 ± 11.25119.4 ± 12.96122.9 ± 15.25125.6 ± 12.21
Sitting systolic BP: change at week 21.3 ± 12.12-1.9 ± 11.86-3.9 ± 14.541.3 ± 13.59-2.4 ± 11.76-3.1 ± 10.461.1 ± 9.814.4 ± 11.68
Sitting systolic BP: change at week 60.6 ± 12.24-7.5 ± 8.67-9.4 ± 8.951.0 ± 14.63-8.4 ± 10.81-0.6 ± 14.40-3.6 ± 8.37-1.5 ± 5.80
Supine diastolic BP: Baseline77.7 ± 9.2875.2 ± 8.7978.8 ± 8.3974.5 ± 8.2675.9 ± 8.7877.5 ± 8.7174.4 ± 8.2073.7 ± 8.59
Supine diastolic BP: change at week 20.5 ± 7.510.6 ± 6.47-0.4 ± 8.501.6 ± 10.331.2 ± 8.32-2.8 ± 6.691.6 ± 8.891.4 ± 7.74
Supine diastolic BP: change at week 6-2.5 ± 7.691.5 ± 7.61-0.7 ± 8.320.5 ± 7.96-0.9 ± 10.65-1.6 ± 6.221.9 ± 9.720.5 ± 6.32
Sitting diastolic BP: Baseline76.5 ± 9.2880.1 ± 6.7677.8 ± 10.0269.6 ± 11.4880.9 ± 8.2175.1 ± 5.7777.1 ± 12.0080.3 ± 7.83
Sitting diastolic BP: change at week 2-1.6 ± 8.490.7 ± 7.930.0 ± 9.441.6 ± 12.00-2.9 ± 10.771.7 ± 8.204.5 ± 5.80-1.2 ± 6.49
Sitting diastolic BP: change at week 60.8 ± 9.900.0 ± 5.79-1.6 ± 11.971.1 ± 15.61-5.3 ± 9.27-2.8 ± 12.60-0.3 ± 7.890.4 ± 8.41
SecondaryChange From Baseline in Vital Signs- Pulse Rate at Weeks 2 and 6
Time frame:
Baseline, Weeks 2 and 6
Reported as:
Mean · Beats per minute
Change From Baseline in Vital Signs- Pulse Rate at Weeks 2 and 6
Beats per minuteVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Baseline69.6 ± 12.5869.5 ± 9.8272.9 ± 14.3067.9 ± 9.3168.8 ± 11.7669.4 ± 11.1570.1 ± 11.1868.2 ± 9.59
Change at week 20.5 ± 10.410.2 ± 8.11-2.5 ± 9.661.1 ± 9.130.5 ± 6.543.7 ± 9.472.8 ± 8.284.1 ± 9.16
Change at week 62.1 ± 10.590.3 ± 8.04-1.4 ± 11.900.9 ± 9.711.8 ± 8.734.1 ± 6.760.5 ± 9.121.8 ± 8.64
SecondaryChange From Baseline in Vital Signs- Temperature at Weeks 2 and 6
Time frame:
Baseline, Weeks 2 and 6
Reported as:
Mean · Degree Celsius
Change From Baseline in Vital Signs- Temperature at Weeks 2 and 6
Degree CelsiusVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Baseline36.5 ± 0.3336.5 ± 0.4336.6 ± 0.4436.6 ± 0.3336.5 ± 0.3736.5 ± 0.2936.6 ± 0.4136.6 ± 0.29
Change at week 2-0.1 ± 0.41-0.1 ± 0.300.0 ± 0.38-0.0 ± 0.430.1 ± 0.35-0.0 ± 0.380.0 ± 0.340.0 ± 0.41
Change at week 6-0.0 ± 0.40-0.0 ± 0.290.0 ± 0.380.1 ± 0.320.0 ± 0.290.1 ± 0.500.0 ± 0.37-0.0 ± 0.46
SecondaryNumber of Participants With Each Severity Grade in Local Tolerability Assessments

Local tolerability skin assessments were performed by the investigator and graded based on severity from grade 0 to 4 as: grade 0=none (no evidence of local intolerance); grade 1=mild (minimal erythema and/or oedema, slight glazed appearance); grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology) grade 3=severe (erythema, oedema glazing with fissures, few vesicles or papules consider removing topical agent \[if still in place\]) and grade 4= very severe (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\]). Higher grades indicated worsening of condition. Only those categories in which at least 1 participant had data were reported.

Time frame:
Day 1 and any day on of Week 1, 2, 4, 6: pre dose (before application of IP) and post dose (after application of IP); Follow up visit (28 days after last dose of study drug = maximum up to Day 71) and Early termination (anytime within week 11)
Reported as:
Count of participants · Participants
Number of Participants With Each Severity Grade in Local Tolerability Assessments
ParticipantsVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
Day 1: tolerability before: none3535313336353436
Day 1: tolerability before: mild00130120
Day 1: tolerability before: moderate22410001
Day 1: tolerability after: none3336303335343233
Day 1: tolerability after: mild10120241
Day 1: tolerability after: moderate11310000
Week 1: tolerability before: none3128283030303333
Week 1: tolerability before: mild12333111
Week 1: tolerability before: moderate20300100
Week 1: tolerability after: none2829293028273231
Week 1: tolerability after: mild22232311
Week 1: tolerability after: moderate20200100
Week 2: tolerability before: none2928263030233133
Week 2: tolerability before: mild32221100
Week 2: tolerability before: moderate10310010
Week 2: tolerability after: none2826293129233230
Week 2: tolerability after: mild13211201
Week 2: tolerability after: moderate10110010
Week 4: tolerability before: none2726303030243131
Week 4: tolerability before: mild02220011
Week 4: tolerability before: moderate10101100
Week 4: tolerability after: none2426303029243130
Week 4: tolerability after: mild12210010
Week 4: tolerability after: moderate10001100
Week 6: tolerability before: none2625293030213032
Week 6: tolerability before: mild11210101
Week 6: tolerability before: moderate00210100
Week 6: tolerability after: none2524282929223030
Week 6: tolerability after: mild01300000
Week 6: tolerability after: moderate00110100
Early termination:tolerability: none65322921
Early termination:tolerability: mild02000001
Early termination:tolerability: moderate20000100
Early termination:tolerability: severe11011000
Follow Up: tolerability: none2226252528252628
Follow Up: tolerability: mild10200111
Follow Up: tolerability: moderate10141100
Follow Up: tolerability: severe00100000

Adverse events

Collected over Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Cream Once Daily (QD)0/37 (0%)0/37 (0%)18/37 (48.6%)
PF-06700841 0.1% Cream QD0/37 (0%)0/37 (0%)17/37 (45.9%)
PF-06700841 0.3% Cream QD0/36 (0%)0/36 (0%)11/36 (30.6%)
PF-06700841 1.0% Cream QD0/37 (0%)0/37 (0%)12/37 (32.4%)
PF-06700841 3.0% Cream QD0/36 (0%)0/36 (0%)10/36 (27.8%)
Vehicle Cream Twice Daily (BID)0/36 (0%)0/36 (0%)17/36 (47.2%)
PF-06700841 0.3% Cream BID0/36 (0%)0/36 (0%)9/36 (25%)
PF-06700841 1.0% Cream BID0/37 (0%)0/37 (0%)14/37 (37.8%)
Most frequent other events
Showing 10 of 86
Most frequent other events
EventVehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BID
NasopharyngitisInfections and infestations1/372/372/363/374/362/362/362/37
Application site pruritusGeneral disorders0/370/370/360/370/363/360/360/37
Dermatitis atopicSkin and subcutaneous tissue disorders3/373/371/360/371/363/360/362/37
Application site erythemaGeneral disorders0/370/370/360/370/362/360/361/37
Urinary tract infectionInfections and infestations1/370/372/362/370/360/360/360/37
CoughRespiratory, thoracic and mediastinal disorders0/370/372/360/370/361/361/360/37
InfluenzaInfections and infestations0/371/370/362/371/360/360/360/37
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/372/371/360/370/360/360/360/37
PruritusSkin and subcutaneous tissue disorders2/371/370/360/370/360/360/360/37
Swelling of eyelidEye disorders0/370/370/360/370/360/361/360/37

Baseline characteristics

Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Vehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BIDTotal
Mean39.1 ± 16.8040.8 ± 15.3543.4 ± 16.4338.4 ± 12.9040.5 ± 12.3042.3 ± 18.1839.4 ± 17.2738.1 ± 15.3440.2 ± 15.59
Sex: Female, Male
Sex: Female, Male(Participants)Vehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BIDTotal
Female2019242315191620156
Male1718121421172017136
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BIDTotal
Hispanic or Latino0032130413
Not Hispanic or Latino3737323535333533277
Unknown or Not Reported001000102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vehicle Cream Once Daily (QD)PF-06700841 0.1% Cream QDPF-06700841 0.3% Cream QDPF-06700841 1.0% Cream QDPF-06700841 3.0% Cream QDVehicle Cream Twice Daily (BID)PF-06700841 0.3% Cream BIDPF-06700841 1.0% Cream BIDTotal
American Indian or Alaska Native000000000
Asian48481099759
Native Hawaiian or Other Pacific Islander000101002
Black or African American8796465651
White2422212021202224174
More than one race002210005
Unknown or Not Reported100000001
08

Study locations

76 sites
  • Clinical Research Center of Alabama, LLC
    Birmingham, Alabama 35244, United States
  • Center for Dermatology and Plastic Surgery/CCT
    Scottsdale, Arizona 85260, United States
  • Center for Dermatology and Plastic Surgery
    Scottsdale, Arizona 85260, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Beach Allergy and Asthma Specialty Group, A Medical Corporation
    Long Beach, California 90808, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • New England Associates, LLC
    Bridgeport, Connecticut 06606, United States
  • Dermatology Physicians of Connecticut
    Shelton, Connecticut 06484, United States
  • Yolanda C. Holmes, MD
    Washington, District of Columbia 20036, United States
  • Olympian Clinical Research
    Clearwater, Florida 33756, United States
  • Accel Research Sites - DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Precision Imaging
    Jacksonville, Florida 32256, United States
  • Solutions Through Advanced Research, Inc
    Jacksonville, Florida 32256, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Leavitt Medical Associates of Florida d/b/a Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Advanced Medical Research PC
    Sandy Springs, Georgia 30328, United States
  • Sneeze, Wheeze & Itch Associates, LLC
    Normal, Illinois 61761, United States
  • DS Research
    New Albany, Indiana 47150, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Meridian Clinical Research, LLC
    Baton Rouge, Louisiana 70808, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Dermatology Consulting Services, PLLC
    High Point, North Carolina 27262, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Vital Prospects Clinical Research Institute, PC
    Tulsa, Oklahoma 74136, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Tanenbaum Dermatology Center
    Memphis, Tennessee 38117, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • studies in Dermatology, LLC
    Cypress, Texas 77433, United States
  • Center for Clinical Studies, LTD.LLP
    Houston, Texas 77004, United States
  • Ventavia Research Group LLC
    Hurst, Texas 76054, United States
  • Center for Clinical Studies, LTD. LLP
    Webster, Texas 77598, United States
  • Summit Clinical Research, LLC
    Franklin, Virginia 23851, United States
  • Virginia Dermatology and Skin Cancer Center
    Norfolk, Virginia 23502, United States
  • Australian Clinical Research Network
    Maroubra, New South Wales 2035, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Cabrini Hospital
    Malvern, Victoria 3144, Australia
  • Center for Skin and Venereal Diseases EOOD - Sofia
    Sofia, 1404, Bulgaria
  • DCC Alexandrovska
    Sofia, 1431, Bulgaria
  • Diagnostic Consultative Center - Fokus-5 - Medical Establishment for Outpatient Care OOD
    Sofia, 1463, Bulgaria
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • SKiN Health
    Cobourg, Ontario K9A 4J9, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2X 2V1, Canada
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Gentofte Hospital
    Hellerup, 2900, Denmark
  • Emovis GmbH
    Berlin, 10629, Germany
  • Rothhaar Studien GmbH
    Berlin, 10783, Germany
  • ISA - Interdisciplinary Study Association GmbH
    Berlin, 10789, Germany
  • Klinikum Bielefeld gem.GmbH
    Bielefeld, 33647, Germany
  • Universitätsklinikum Bonn AöR
    Bonn, 53127, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt, 60590, Germany
  • MENSINGDERMA research GmbH
    Hamburg, 22391, Germany
  • MVZ Alstermed GmbH
    Hamburg, 22391, Germany
  • Dermatologische Gemeinschaftspraxis
    Mahlow, 15831, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • Semmelweis Egyetem Altalanos Orvostudomanyi Kar
    Budapest, 1085, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Bacs-Kiskun Megyei Korhaz Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar Oktato Korhaza
    Kecskemet, 6000, Hungary
  • CRU Hungary Kft.
    Miskolc, 3529, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, 6720, Hungary
  • Kitago Dermatology Clinic
    Sapporo-shi, Hokkaido 003-0833, Japan
  • Nakatsuhifuka Clinic
    Kita-ku, Osaka-shi, Osaka 531-0072, Japan
  • Parkside Hiroo Ladies Clinic
    Minato-ku, Tokyo 106-0047, Japan
  • Tanpopo Skin Clinic
    Ota Ku, Tokyo 143-0023, Japan
  • Shinjuku Minamiguchi Dermatology Skin Clinic
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Medical Corporation Jitai-kai Tachikawa Dermatology Clinic
    Tachikawa, Tokyo 190-0023, Japan
  • Aesthetic dermatology clinic of Prof. J. Kisis
    Riga, LV-1003, Latvia
  • Health and Aesthetics Ltd
    Riga, LV-1009, Latvia
  • Outpatient Clinic of Ventspils
    Ventspils, LV3601, Latvia
  • NZOZ Specjalistyczny Ośrodek Dermatologiczny DERMAL s.c.
    Bialystok, 15-453, Poland
  • NASZ LEKARZ Przychodnie Medyczne
    Torun, 87-100, Poland
  • MTZ Clinical Research Sp. z o.o
    Warszawa, 02-106, Poland
  • WroMedica I. Bielicka, A. Strzalkowska s.c.
    Wroclaw, 51-685, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in May 2020, 11 months.

Results were first posted in Mar 2021, 10 months after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 11 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2019
First posted
Apr 4, 2019
StartActual
May 13, 2019
Primary completionActual
May 7, 2020
CompletionActual
May 7, 2020
Results first posted
Mar 29, 2021
Last update
Mar 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03903822
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 4, 2019
Start date
May 13, 2019
Primary completion
May 7, 2020
Completion
May 7, 2020
Results posted
Mar 29, 2021
Last update
Mar 29, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06700841

Start the discussion